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___________________________________________________________________ 
 
“Building Japanese and U.S. Alliances among Government, Academia, and Industry” 
was the topic of the fourth annual Philadelphia-Japan Health Science Dialogue held in 
Philadelphia this past February. The event, which was sponsored by the Japan 
America Society of Greater Philadelphia, drew approximately 70 attendees from a 
spectrum of organizations, both U.S. and Japanese. 
 
Opening remarks, delivered by Paul C. Brucker, MD, President of Thomas Jefferson 
University, stressed the importance of government, industry, and academic alliances 
in an environment such as Philadelphia’s, with its concentration of related 
organizations and centers. Dr. Brucker pointed out that the translation of scientific 
inventions from the laboratory to the commercial market has not always received the 
attention it deserves, but that with the passage of the Bayh-Dole Act in 1981, 
partnerships between academia and industry have been greatly fostered at 
institutions across the country, including Jefferson. Such cooperation has translated 
into dramatic increases in the research budget and provided benefits to everyone: 
patients, the regional economy, and investors. 
 
Frank Baldino, Jr., PhD, Chairman and CEO of Cephalon, a Pennsylvania biotech 
company, used the opportunity during his keynote address to discuss specifically the 
significance of alliances in the global pharmaceutical industry. Such alliances, he 
said, have the “power to transform companies and industries.” The government, 
academic centers, and industries need each other to survive, but the relationships 
among them remain tenuous. While there exist numerous examples of successful 
and prosperous relationships that have been formed, such as that between Stanford 
University and GenoTech, the creation of more alliances can only serve to balance 
risk, particularly risk inherent to the biotech industry. Partnerships between large 
and small companies, early stage and late stage programs, and second or third 
generation and cutting edge products are all examples of the types of alliances which 
Dr. Baldino suggested can foster more stability for the industry, allowing innovation 
to take place within a sound business strategy. 
 
The benefits of industry-university cooperation were the focus of a panel discussion 
that outlined some of the differences between the Japanese and U.S. systems, while 
stressing the commonality of many of the goals. Louis P. Berneman, the Managing 
Director of the University of Pennsylvania Center for Technology Transfer, pointed to 
the positive economic impact of cooperative efforts between industry and universities 
if the two can overcome some of their inherent conflicting values. Akio Nishizawa, 
PhD, from Tohoku University in Miyagi, Japan, described recent developments in 
Japan that stress the importance of technology transfer to help rejuvenate the ailing 
economy. The Japanese government has created technology licensing organizations 
(TLOs), of which 28 existed in 2002, to occupy the space between universities and 
industry, hoping to create an impact similar to that of the Bayh-Dole Act. However, 
the impact of TLOs has so far been small, and Dr. Nishizawa maintained that 
dramatic structural changes would be necessary to promote true tri-lateral networks 
among the state, academia, and industry. Biotechnology business strategy and 
global alliances were addressed by Yoshio Matsumi, Executive Councillor, 
International Affairs for Itochu Corporation. Mr. Matsumi described Itochu’s business 
strategy, which includes a focus on strategic alliances with companies and academic 
centers in the U.S., the European Union, Australia, and Japan. During the discussion 
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period, the three panelists voiced opinions on, among other issues, different ways 
that larger pharmaceutical companies can work with universities in the U.S. and 
Japan. 
 
Afternoon speakers included Mark Schweiker, President and CEO, Greater 
Philadelphia Chamber of Commerce and former Governor of Pennsylvania; Roger 
Longman, Managing Partner, Windover Information, Inc.; Michael Devlin, Partner, 
McKinsey and Company, Tokyo; Takahiko Iwaya, Director, Health and Welfare 
Department, JETRO New York; Leslie Alexandre, President and CEO, North Carolina 
Biotechnology Center; and Edward Lentz, Of Counsel, Intellectual Property, Morgan, 
Lewis and Bockius. The various topics covered, including the drivers behind U.S. and 
Japanese alliances, elicited numerous questions from the audience. 
 
Throughout the day, the value of and need for frequent and mutually beneficial 
alliances among government, academia, and industry were stressed. Mutual 
understanding of differences in cultures, both international and organizational, 
remains a crucial factor in the creation of solid relationships. Benefits from alliances, 
however, can far outweigh any difficulties encountered from overcoming obstacles 
and can provide the means by which creative invention, strategic commercialization, 
and financial benefit are merged to the advantage of all stakeholders. 
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